Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 23 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Apr 2026 Results presented in the Alexion, AstraZeneca Rare Disease Media Release
10 Apr 2026 According to a Alexion, AstraZeneca Rare Disease media release, data from the trial will be presented at the American Academy of Neurology (AAN) Annual Meeting in Chicago, Illinois, 18 to 22 April 2026.
06 Nov 2025 According to an AstraZeneca media release, based on results from this trial, the company has filed a regulatory application in Japan for Gefurulimab to treat generalized myasthenia gravis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com